FINNENCE ▪ THE WIRE FILE

THE WIRE · № 83936

News■ Unclear/unknown

Iambic Therapeutics raises USD 150m in Nasdaq IPO

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-16 10:24 UTC

KINDNews

DIRECTION■ Unclear/unknown

SOURCES1

ENTITIES3

STORY SIZESTANDALONE

FIRST SEEN2026-10-16 10:24 UTC

LAST UPDATE2026-10-16 10:24 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A $150M Nasdaq biotech IPO adds to a cluster of new listings, signaling reopening IPO windows for drug developers.

Another biotech IPO tests listing window

CATALYST TO WATCH

Pricing and post-IPO performance

MAIN RISK

Poor debut chills biotech issuance

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

SUBJECTNasdaq Composite · ^IXIC

AFFECTEDHealthcare

AFFECTEDSPDR Biotech ETF · XBI

04 RECEIPTS

THE SOURCE RECORD.

2 SOURCES CONFIRMED

№ 01googlenewsnews.google.com · CONFIRMING2026-10-16 10:24 UTCOPEN RECEIPT →

№ 02googlenewsnews.google.com · PRIMARY2026-10-16 10:24 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

→CORRELATIONshares Healthcare, XBI
Next-gen RNAi drugmaker City prices $200M IPO2026-10-16 10:53 UTC

→CORRELATIONshares Healthcare
Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)2026-10-16 11:12 UTC

→CORRELATIONshares Healthcare
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development2026-10-16 11:30 UTC

→CORRELATIONshares Healthcare
New Phase 3 trial: A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. — AstraZeneca2026-10-16 12:00 UTC

→CORRELATIONshares Healthcare
Phase 3 results posted: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics2026-10-16 12:00 UTC

→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin — Eli Lilly and Company2026-10-16 12:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.